Wall Street brokerages expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings of $1.92 per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.28) and the highest estimate coming in at $4.36. Esperion Therapeutics posted earnings of ($2.01) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 195.5%. The firm is scheduled to announce its next quarterly earnings results on Thursday, August 13th.
On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($5.05) per share for the current financial year, with EPS estimates ranging from ($6.27) to ($3.61). For the next financial year, analysts forecast that the company will report earnings of ($8.49) per share, with EPS estimates ranging from ($11.69) to ($3.55). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($3.14) by $0.30. Esperion Therapeutics had a negative net margin of 5,492.02% and a negative return on equity of 627.38%. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.39 million. During the same period last year, the firm earned $3.07 EPS. The business’s quarterly revenue was down 98.8% compared to the same quarter last year.
A number of equities research analysts recently weighed in on the stock. ValuEngine upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, April 21st. Stifel Nicolaus reiterated a “buy” rating and issued a $75.00 target price on shares of Esperion Therapeutics in a research note on Friday, June 26th. Jefferies Financial Group decreased their price objective on Esperion Therapeutics from $85.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Needham & Company LLC reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, May 7th. Finally, Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Thursday, March 26th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $78.50.
Large investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new position in shares of Esperion Therapeutics in the fourth quarter valued at approximately $1,416,000. Brinker Capital Inc. bought a new position in Esperion Therapeutics during the 4th quarter worth $462,000. Janus Henderson Group PLC acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth $234,000. Mutual of America Capital Management LLC acquired a new position in shares of Esperion Therapeutics in the first quarter valued at about $1,016,000. Finally, Amalgamated Bank bought a new position in Esperion Therapeutics during the fourth quarter worth about $277,000.
Esperion Therapeutics stock traded up $0.49 during mid-day trading on Thursday, hitting $51.31. The company’s stock had a trading volume of 20,501 shares, compared to its average volume of 646,895. The stock has a market cap of $1.40 billion, a PE ratio of -5.29 and a beta of 2.13. Esperion Therapeutics has a one year low of $24.82 and a one year high of $76.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 2.35. The company has a 50 day moving average of $44.93 and a 200-day moving average of $48.15.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
See Also: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.